James R Christensen1,2,3, Beth S Slomine2,4,5, Faye S Silverstein6,7, Kent Page8, Richard Holubkov8, J Michael Dean8, Frank W Moler6. 1. Department of Pediatric Rehabilitation Medicine, Kennedy Krieger Institute, Baltimore, MD. 2. Department of Physical Medicine and Rehabilitation, Johns Hopkins University, Baltimore, MD. 3. Department of Pediatrics, Johns Hopkins University, Baltimore, MD. 4. Department of Neuropsychology, Kennedy Krieger Institute, Baltimore, MD. 5. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD. 6. Department of Pediatrics, University of Michigan, Ann Arbor, MI. 7. Department of Neurology, University of Michigan, Ann Arbor, MI. 8. Department of Pediatrics, University of Utah, Salt Lake City, UT.
Abstract
OBJECTIVES: To describe survival and 3-month and 12-month neurobehavioral outcomes in children with preexisting neurobehavioral impairment enrolled in one of two parallel randomized clinical trials of targeted temperature management. DESIGN: Secondary analysis of Therapeutic Hypothermia after Pediatric Cardiac Arrest In-Hospital and Out-of-Hospital trials data. SETTING: Forty-one PICUs in the United States, Canada, and United Kingdom. PATIENTS: Eighty-four participants (59 in-hospital cardiac arrest and 25 out-of-hospital cardiac arrest), 49 males, 35 females, mean age 4.6 years (SD, 5.36 yr), with precardiac arrest neurobehavioral impairment (Vineland Adaptive Behavior Scales, Second Edition composite score < 70). All required chest compressions for greater than or equal to 2 minutes, were comatose and required mechanical ventilation after return of circulation. INTERVENTIONS:Neurobehavioral function was assessed using the Vineland Adaptive Behavior Scales, Second Edition at baseline (reflecting precardiac arrest status), and at 3 and 12 months postcardiac arrest, followed by on-site cognitive evaluation. Vineland Adaptive Behavior Scales, Second Edition norms are 100 (mean) ± 15 (SD); higher scores indicate better function. Analyses evaluated survival, changes in Vineland Adaptive Behavior Scales, Second Edition, and cognitive functioning. MEASUREMENTS AND MAIN RESULTS:Twenty-eight of 84 (33%) survived to 12 months (in-hospital cardiac arrest, 19/59 (32%); out-of-hospital cardiac arrest, 9/25 [36%]). In-hospital cardiac arrest (but not out-of-hospital cardiac arrest) survival rate was significantly lower compared with the Therapeutic Hypothermia after Pediatric Cardiac Arrest group without precardiac arrest neurobehavioral impairment. Twenty-five survived with decrease in Vineland Adaptive Behavior Scales, Second Edition less than or equal to 15 (in-hospital cardiac arrest, 18/59 (31%); out-of-hospital cardiac arrest, 7/25 [28%]). At 3-months postcardiac arrest, mean Vineland Adaptive Behavior Scales, Second Edition scores declined significantly (-5; SD, 14; p < 0.05). At 12 months, Vineland Adaptive Behavior Scales, Second Edition declined after out-of-hospital cardiac arrest (-10; SD, 12; p < 0.05), but not in-hospital cardiac arrest (0; SD, 15); 43% (12/28) had unchanged or improved scores. CONCLUSIONS: This study demonstrates the feasibility, utility, and challenge of including this population in clinical neuroprotection trials. In children with preexisting neurobehavioral impairment, one-third survived to 12 months and their neurobehavioral outcomes varied broadly.
RCT Entities:
OBJECTIVES: To describe survival and 3-month and 12-month neurobehavioral outcomes in children with preexisting neurobehavioral impairment enrolled in one of two parallel randomized clinical trials of targeted temperature management. DESIGN: Secondary analysis of Therapeutic Hypothermia after Pediatric Cardiac Arrest In-Hospital and Out-of-Hospital trials data. SETTING: Forty-one PICUs in the United States, Canada, and United Kingdom. PATIENTS: Eighty-four participants (59 in-hospital cardiac arrest and 25 out-of-hospital cardiac arrest), 49 males, 35 females, mean age 4.6 years (SD, 5.36 yr), with precardiac arrest neurobehavioral impairment (Vineland Adaptive Behavior Scales, Second Edition composite score < 70). All required chest compressions for greater than or equal to 2 minutes, were comatose and required mechanical ventilation after return of circulation. INTERVENTIONS: Neurobehavioral function was assessed using the Vineland Adaptive Behavior Scales, Second Edition at baseline (reflecting precardiac arrest status), and at 3 and 12 months postcardiac arrest, followed by on-site cognitive evaluation. Vineland Adaptive Behavior Scales, Second Edition norms are 100 (mean) ± 15 (SD); higher scores indicate better function. Analyses evaluated survival, changes in Vineland Adaptive Behavior Scales, Second Edition, and cognitive functioning. MEASUREMENTS AND MAIN RESULTS: Twenty-eight of 84 (33%) survived to 12 months (in-hospital cardiac arrest, 19/59 (32%); out-of-hospital cardiac arrest, 9/25 [36%]). In-hospital cardiac arrest (but not out-of-hospital cardiac arrest) survival rate was significantly lower compared with the Therapeutic Hypothermia after Pediatric Cardiac Arrest group without precardiac arrest neurobehavioral impairment. Twenty-five survived with decrease in Vineland Adaptive Behavior Scales, Second Edition less than or equal to 15 (in-hospital cardiac arrest, 18/59 (31%); out-of-hospital cardiac arrest, 7/25 [28%]). At 3-months postcardiac arrest, mean Vineland Adaptive Behavior Scales, Second Edition scores declined significantly (-5; SD, 14; p < 0.05). At 12 months, Vineland Adaptive Behavior Scales, Second Edition declined after out-of-hospital cardiac arrest (-10; SD, 12; p < 0.05), but not in-hospital cardiac arrest (0; SD, 15); 43% (12/28) had unchanged or improved scores. CONCLUSIONS: This study demonstrates the feasibility, utility, and challenge of including this population in clinical neuroprotection trials. In children with preexisting neurobehavioral impairment, one-third survived to 12 months and their neurobehavioral outcomes varied broadly.
Authors: Farhan Bhanji; Alexis A Topjian; Vinay M Nadkarni; Amy H Praestgaard; Elizabeth A Hunt; Adam Cheng; Peter A Meaney; Robert A Berg Journal: JAMA Pediatr Date: 2017-01-01 Impact factor: 16.193
Authors: Frank W Moler; Kathleen Meert; Amy E Donaldson; Vinay Nadkarni; Richard J Brilli; Heidi J Dalton; Robert S B Clark; Donald H Shaffner; Charles L Schleien; Kimberly Statler; Kelly S Tieves; Richard Hackbarth; Robert Pretzlaff; Elise W van der Jagt; Fiona Levy; Lynn Hernan; Faye S Silverstein; J Michael Dean Journal: Crit Care Med Date: 2009-07 Impact factor: 7.598
Authors: Beth S Slomine; Vinay M Nadkarni; James R Christensen; Faye S Silverstein; Russell Telford; Alexis Topjian; Joshua D Koch; Jill Sweney; Ericka L Fink; Mudit Mathur; Richard Holubkov; J Michael Dean; Frank W Moler Journal: Resuscitation Date: 2017-03-06 Impact factor: 5.262
Authors: Frank W Moler; Faye S Silverstein; Richard Holubkov; Beth S Slomine; James R Christensen; Vinay M Nadkarni; Kathleen L Meert; Brittan Browning; Victoria L Pemberton; Kent Page; Marianne R Gildea; Barnaby R Scholefield; Seetha Shankaran; Jamie S Hutchison; John T Berger; George Ofori-Amanfo; Christopher J L Newth; Alexis Topjian; Kimberly S Bennett; Joshua D Koch; Nga Pham; Nikhil K Chanani; Jose A Pineda; Rick Harrison; Heidi J Dalton; Jeffrey Alten; Charles L Schleien; Denise M Goodman; Jerry J Zimmerman; Utpal S Bhalala; Adam J Schwarz; Melissa B Porter; Samir Shah; Ericka L Fink; Patrick McQuillen; Theodore Wu; Sophie Skellett; Neal J Thomas; Jeffrey E Nowak; Paul B Baines; John Pappachan; Mudit Mathur; Eric Lloyd; Elise W van der Jagt; Emily L Dobyns; Michael T Meyer; Ronald C Sanders; Amy E Clark; J Michael Dean Journal: N Engl J Med Date: 2017-01-24 Impact factor: 91.245
Authors: Kathleen Meert; Russell Telford; Richard Holubkov; Beth S Slomine; James R Christensen; John Berger; George Ofori-Amanfo; Christopher J L Newth; J Michael Dean; Frank W Moler Journal: Resuscitation Date: 2018-01-06 Impact factor: 6.251
Authors: Beth S Slomine; Faye S Silverstein; James R Christensen; Richard Holubkov; Kent Page; J Michael Dean; Frank W Moler Journal: Pediatrics Date: 2016-03-03 Impact factor: 7.124
Authors: José A Hordijk; Sascha C Verbruggen; Corinne M Buysse; Elisabeth M Utens; Koen F Joosten; Karolijn Dulfer Journal: Qual Life Res Date: 2022-03-31 Impact factor: 3.440